Key clinical point: For patients with localized renal cell carcinoma (RCC), stereotactic ablative body radiotherapy (SABR) may be an effective treatment alternative to surgery.

Major finding: Median overall survival was 92 months among patients with renal tumors no larger than 2.5 cm.

Study details: A retrospective study involving 347 patients with localized renal cell carcinoma (RCC) who were treated with stereotactic ablative body radiotherapy.

Disclosures: No external funding was provided for the study and the investigators reported having no conflicts of interest.

Wegner RE et al. Adv Rad Onc. 2019 Aug 8. doi: 10.1016/j.adro.2019.07.018.